-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 25, Osaikang once again submitted the 2 new drug listing application of dexlansoprazole for injecti.
Takeda Pharmaceutical's dexlansoprazole is only available in oral preparations, and it will sell more than 57 billion yen (about 400 million US dollars) globally in 202 At present, there are no imported or domestically approved products of this variety in the domestic mark.
Takeda Pharmaceutical's dexlansoprazole is only available in oral preparations, and it will sell more than 57 billion yen (about 400 million US dollars) globally in 202 At present, there are no imported or domestically approved products of this variety in the domestic mark.
Figure 1: Osaikang's latest reported products
Source: CDE official website
Dexlansoprazole is a proton pump inhibitor and is the R-isomer of lansoprazo.
Takeda's dexlansoprazole enteric-coated capsules were first launched in the United States in 2009 for the maintenance of various degrees of erosive esophagitis, non-erosive reflux esophagitis and related sympto.
The product will be available in 202 global sales of more than 57 billion yen (about 400 million US dollar.
Takeda's dexlansoprazole enteric-coated capsules were first launched in the United States in 2009 for the maintenance of various degrees of erosive esophagitis, non-erosive reflux esophagitis and related sympto.
The product will be available in 202 global sales of more than 57 billion yen (about 400 million US dollar.
Figure 2: Domestic pharmaceutical companies reported the production of dexlansoprazole-related products
Source: New version of Min.
com
com
According to data from Min.
com, both Chia Tai Tianqing Pharmaceutical Group and Hansoh Pharmaceutical Group submitted three types of generic marketing applications for dexlansoprazole enteric-coated capsules, which were finally approved for clinical u.
Prazol has attracted two domestic pharmaceutical companies to participate in the competiti.
At present, the acceptance number of Shenghe (China) Biopharmaceuticals is still under review and approval, while Osaikang voluntarily withdrew the acceptance number earlier and applied again after supplementing the informati.
Grab the first domestic one, we will wait and s.
com, both Chia Tai Tianqing Pharmaceutical Group and Hansoh Pharmaceutical Group submitted three types of generic marketing applications for dexlansoprazole enteric-coated capsules, which were finally approved for clinical u.
Prazol has attracted two domestic pharmaceutical companies to participate in the competiti.
At present, the acceptance number of Shenghe (China) Biopharmaceuticals is still under review and approval, while Osaikang voluntarily withdrew the acceptance number earlier and applied again after supplementing the informati.
Grab the first domestic one, we will wait and s.
Figure 3: The sales ratio of Osaikang's fist PPI preparations in 2021
Source: Min.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
As the first echelon of domestic PPI preparations, Osaikang currently has five major products, all of which are injectio.
In 2021, the total sales in China's public medical institutions will exceed 3 billion yu.
In 2021, the total sales in China's public medical institutions will exceed 3 billion yu.
In addition to the 2 class new drug dexlansoprazole for injection reported this time, Osaikang also has two PPI preparations, dexlansoprazole sodium for injection and esomeprazole magnesium enteric dry suspensi.
Category 3 generic marketing applications are under review and approv.
Category 3 generic marketing applications are under review and approv.
Source: CDE official website, Minet database
On May 25, Osaikang once again submitted the 2 new drug listing application of dexlansoprazole for injecti.
Takeda Pharmaceutical's dexlansoprazole is only available in oral preparations, and it will sell more than 57 billion yen (about 400 million US dollars) globally in 202 At present, there are no imported or domestically approved products of this variety in the domestic mark.
Takeda Pharmaceutical's dexlansoprazole is only available in oral preparations, and it will sell more than 57 billion yen (about 400 million US dollars) globally in 202 At present, there are no imported or domestically approved products of this variety in the domestic mark.
Figure 1: Osaikang's latest reported products
Source: CDE official website
Dexlansoprazole is a proton pump inhibitor and is the R-isomer of lansoprazo.
Takeda's dexlansoprazole enteric-coated capsules were first launched in the United States in 2009 for the maintenance of various degrees of erosive esophagitis, non-erosive reflux esophagitis and related sympto.
The product will be available in 202 global sales of more than 57 billion yen (about 400 million US dollar.
Takeda's dexlansoprazole enteric-coated capsules were first launched in the United States in 2009 for the maintenance of various degrees of erosive esophagitis, non-erosive reflux esophagitis and related sympto.
The product will be available in 202 global sales of more than 57 billion yen (about 400 million US dollar.
Figure 2: Domestic pharmaceutical companies reported the production of dexlansoprazole-related products
Source: New version of Min.
com
com
According to data from Min.
com, both Chia Tai Tianqing Pharmaceutical Group and Hansoh Pharmaceutical Group submitted three types of generic marketing applications for dexlansoprazole enteric-coated capsules, which were finally approved for clinical u.
Prazol has attracted two domestic pharmaceutical companies to participate in the competiti.
At present, the acceptance number of Shenghe (China) Biopharmaceuticals is still under review and approval, while Osaikang voluntarily withdrew the acceptance number earlier and applied again after supplementing the informati.
Grab the first domestic one, we will wait and s.
com, both Chia Tai Tianqing Pharmaceutical Group and Hansoh Pharmaceutical Group submitted three types of generic marketing applications for dexlansoprazole enteric-coated capsules, which were finally approved for clinical u.
Prazol has attracted two domestic pharmaceutical companies to participate in the competiti.
At present, the acceptance number of Shenghe (China) Biopharmaceuticals is still under review and approval, while Osaikang voluntarily withdrew the acceptance number earlier and applied again after supplementing the informati.
Grab the first domestic one, we will wait and s.
Figure 3: The sales ratio of Osaikang's fist PPI preparations in 2021
Source: Min.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
As the first echelon of domestic PPI preparations, Osaikang currently has five major products, all of which are injectio.
In 2021, the total sales in China's public medical institutions will exceed 3 billion yu.
In 2021, the total sales in China's public medical institutions will exceed 3 billion yu.
In addition to the 2 class new drug dexlansoprazole for injection reported this time, Osaikang also has two PPI preparations, dexlansoprazole sodium for injection and esomeprazole magnesium enteric dry suspensi.
Category 3 generic marketing applications are under review and approv.
Category 3 generic marketing applications are under review and approv.
Source: CDE official website, Minet database
On May 25, Osaikang once again submitted the 2 new drug listing application of dexlansoprazole for injecti.
Takeda Pharmaceutical's dexlansoprazole is only available in oral preparations, and it will sell more than 57 billion yen (about 400 million US dollars) globally in 202 At present, there are no imported or domestically approved products of this variety in the domestic mark.
Takeda Pharmaceutical's dexlansoprazole is only available in oral preparations, and it will sell more than 57 billion yen (about 400 million US dollars) globally in 202 At present, there are no imported or domestically approved products of this variety in the domestic mark.
Figure 1: Osaikang's latest reported products
Source: CDE official website
Dexlansoprazole is a proton pump inhibitor and is the R-isomer of lansoprazo.
Takeda's dexlansoprazole enteric-coated capsules were first launched in the United States in 2009 for the maintenance of various degrees of erosive esophagitis, non-erosive reflux esophagitis and related sympto.
The product will be available in 202 global sales of more than 57 billion yen (about 400 million US dollar.
Takeda's dexlansoprazole enteric-coated capsules were first launched in the United States in 2009 for the maintenance of various degrees of erosive esophagitis, non-erosive reflux esophagitis and related sympto.
The product will be available in 202 global sales of more than 57 billion yen (about 400 million US dollar.
Figure 2: Domestic pharmaceutical companies reported the production of dexlansoprazole-related products
Source: New version of Min.
com
com
According to data from Min.
com, both Chia Tai Tianqing Pharmaceutical Group and Hansoh Pharmaceutical Group submitted three types of generic marketing applications for dexlansoprazole enteric-coated capsules, which were finally approved for clinical u.
Prazol has attracted two domestic pharmaceutical companies to participate in the competiti.
At present, the acceptance number of Shenghe (China) Biopharmaceuticals is still under review and approval, while Osaikang voluntarily withdrew the acceptance number earlier and applied again after supplementing the informati.
Grab the first domestic one, we will wait and s.
com, both Chia Tai Tianqing Pharmaceutical Group and Hansoh Pharmaceutical Group submitted three types of generic marketing applications for dexlansoprazole enteric-coated capsules, which were finally approved for clinical u.
Prazol has attracted two domestic pharmaceutical companies to participate in the competiti.
At present, the acceptance number of Shenghe (China) Biopharmaceuticals is still under review and approval, while Osaikang voluntarily withdrew the acceptance number earlier and applied again after supplementing the informati.
Grab the first domestic one, we will wait and s.
Figure 3: The sales ratio of Osaikang's fist PPI preparations in 2021
Source: Min.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
As the first echelon of domestic PPI preparations, Osaikang currently has five major products, all of which are injectio.
In 2021, the total sales in China's public medical institutions will exceed 3 billion yu.
In 2021, the total sales in China's public medical institutions will exceed 3 billion yu.
In addition to the 2 class new drug dexlansoprazole for injection reported this time, Osaikang also has two PPI preparations, dexlansoprazole sodium for injection and esomeprazole magnesium enteric dry suspensi.
Category 3 generic marketing applications are under review and approv.
Category 3 generic marketing applications are under review and approv.
Source: CDE official website, Minet database
Source: CDE official website, Minet database 
